Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All ivermectin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19ivm.org COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: A matched case-control study

Behera et al., PLoS ONE, doi:10.1371/journal.pone.0247163 (date from preprint)
Nov 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Case 54% Improvement Relative Risk Case (b) 44% Ivermectin for COVID-19  Behera et al.  Prophylaxis Does ivermectin reduce COVID-19 infections? Retrospective 372 patients in India Fewer cases with ivermectin (p=0.0007) c19ivm.org Behera et al., PLoS ONE, November 2020 Favorsivermectin Favorscontrol 0 0.5 1 1.5 2+
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
 
*, now with p < 0.00000000001 from 104 studies, recognized in 23 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 79 treatments. c19ivm.org
Retrospective matched case-control prophylaxis study for HCQ, ivermectin, and vitamin C with 372 healthcare workers, showing lower COVID-19 incidence for all treatments, with statistical significance reached for ivermectin.
HCQ OR 0.56, p = 0.29
Ivermectin OR 0.27, p < 0.001
Vitamin C OR 0.82, p = 0.58
This is the 16th of 104 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 1 sextillion).
51 studies are RCTs, which show efficacy with p=0.00000015.
Study covers vitamin C, ivermectin, and HCQ.
risk of case, 53.8% lower, RR 0.46, p < 0.001, treatment 41 of 117 (35.0%), control 145 of 255 (56.9%), NNT 4.6, adjusted per study, odds ratio converted to relative risk, model 2 2+ doses conditional logistic regression.
risk of case, 44.5% lower, RR 0.56, p = 0.007, treatment 41 of 117 (35.0%), control 145 of 255 (56.9%), NNT 4.6, odds ratio converted to relative risk, matched pair analysis.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Behera et al., 3 Nov 2020, retrospective, India, peer-reviewed, 13 authors, dosage 300μg/kg days 1, 4.
This PaperIvermectinAll
Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: A matched case-control study
Priyamadhaba Behera, Binod Kumar Patro, Arvind Kumar Singh, Pradnya Dilip Chandanshive, Ravikumar S. R., Somen Kumar Pradhan, Siva Santosh Kumar Pentapati, Gitanjali Batmanabane, Prasanta Raghab Mohapatra, Biswa Mohan Padhy, Shakti Kumar Bal, Sudipta Ranjan Singh, Rashmi Ranjan Mohanty
PLOS ONE, doi:10.1371/journal.pone.0247163
Background Ivermectin is one among several potential drugs explored for its therapeutic and preventive role in SARS-CoV-2 infection. The study was aimed to explore the association between ivermectin prophylaxis and the development of SARS-CoV-2 infection among healthcare workers. Methods A hospital-based matched case-control study was conducted among healthcare workers of AIIMS Bhubaneswar, India, from September to October 2020. Profession, gender, age and date of diagnosis were matched for 186 case-control pairs. Cases and controls were healthcare workers who tested positive and negative, respectively, for COVID-19 by RT-PCR. Exposure was defined as the intake of ivermectin and/or hydroxychloroquine and/or vitamin-C and/or other prophylaxis for COVID-19. Data collection and entry was done in Epicol-lect5, and analysis was performed using STATA version 13. Conditional logistic regression models were used to describe the associated factors for SARS-CoV-2 infection. Results Ivermectin prophylaxis was taken by 76 controls and 41 cases. Two-dose ivermectin prophylaxis (AOR 0.27, 95% CI, 0.15-0.51) was associated with a 73% reduction of SARS-CoV-2 infection among healthcare workers for the following month. Those involved in physical activity (AOR 3.06 95% CI, 1.18-7.93) for more than an hour/day were more likely to contract SARS-CoV-2 infection. Type of household, COVID duty, single-dose ivermectin
Supporting information S1 Appendix. Questionnaire used in the study (English and Odia language). (PDF) S1 Protocol. Study protocol. (DOC) Author Contributions
References
Ağalar, Engin, Protective measures for COVID-19 for healthcare providers and laboratory personnel, Turk J Med Sci, doi:10.3906/sag-2004-132
Biancatelli, Berrill, Catravas, Marik, Quercetin and vitamin C: an experimental, synergistic therapy for the prevention and treatment of SARS-CoV-2 related disease (COVID-19), Front Immunol, doi:10.3389/fimmu.2020.01451
Boulware, Pullen, Bangdiwala, Pastick, Lofgren et al., A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19, N Engl J Med, doi:10.1056/NEJMoa2016638
Caly, Druce, Catton, Jans, Wagstaff, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res, doi:10.1016/j.antiviral.2020.104787
Chang, Figueredo, COVID-19: ivermectin prophylaxis in adult contacts. First Report on Health Personnel and Post-Exposure Prophylaxis, Research Gate
Cheng, Kogan, Davis, Ascorbate as Prophylaxis and Therapy for COVID-19-Update From Shanghai and US Medical Institutions, Glob Adv Health Med, doi:10.1177/2164956120934768
Feyaerts, Luyten, Vitamin C as prophylaxis and adjunctive medical treatment for COVID-19? Nutrition, doi:10.1016/j.nut.2020.110948
Galvin, Li, Malwade, Syed-Abdul, COVID-19 preventive measures showing an unintended decline in infectious diseases in Taiwan, Int J Infect Dis, doi:10.1016/j.ijid.2020.06.062
Galvis, Spinelli, Tello, Sossa, Higuera et al., Hydroxychloroquine as prophylaxis for coronavirus SARS-CoV-2 infection: review of the ongoing clinical trials, Arch Bronconeumol, doi:10.1016/j.arbres.2020.05.008
Geremia, Vito, Gunnella, Fiore, Princic et al., A Case of Vasculities-Like Skin Eruption Associated With COVID-19, Infectious Diseases in Clinical Practice
Guarneri, Rullo, Pavone, Berretta, Ceccarelli et al., Silent COVID-19: what your skin can reveal, Infectious Diseases, doi:10.1016/S1473-3099%2820%2930402-3
Lahiri, Jha, Bhattacharya, Ray, Chakraborty, Effectiveness of preventive measures against COVID-19: A systematic review of In Silico modeling studies in indian context, Indian J Public Health, doi:10.4103/ijph.IJPH%5F464%5F20
Mahmud, A Phase III Trial to Promote Recovery From Covid 19 With Combined Doxycycline and Ivermectin Along Standard Care
Nmaster, Version2.0-Sample Size Software
Qian, Jiang, COVID-19 and social distancing, Z Gesundh Wiss, doi:10.1007/s10389-020-01321-z
Rajter, Sherman, Fatteh, Vogel, Sacks et al., Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID-19 (ICON study), Chest, doi:10.1016/j.chest.2020.10.009
Sant'ana, Imoto, Amorim, Taminato, Peccin et al., Infection and death in healthcare workers due to COVID-19: a systematic review, Acta Paul Enferm
Shouman, Use of Ivermectin as a Prophylactic Option in Asymptomatic Family Close Contact for Patient With COVID-19
Teslya, Pham, Godijk, Kretzschmar, Bootsma et al., Impact of self-imposed prevention measures and short-term government intervention on mitigating and delaying a COVID-19 epidemic: A modelling study, PLOS Medicine, doi:https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003166
Vaira, Deiana, Fois, Pirina, Madeddu et al., Objective evaluation of anosmia and ageusia in COVID-19 patients: Single-center experience on 72 cases
Vaira, Hopkins, Salzano, Petrocelli, Melis et al., Olfactory and gustatory function impairment in COVID-19 patients: Italian objective multicenter-study, Head & Neck, doi:10.1002/hed.26269
Vito, Geremia, Fiore, Princic, Babudieri et al., Clinical features, laboratory findings and predictors of death in hospitalized patients with COVID-19 in Sardinia, Italy, Eur Rev Med Pharmacol Sci, doi:10.26355/eurrev%5F202007%5F22291
Wang, Pasco, Du, Petty, Fox et al., Impact of social distancing measures on coronavirus disease healthcare demand, central Texas, USA, Emerg Infect Dis, doi:10.3201/eid2610.201702
{ 'indexed': {'date-parts': [[2024, 3, 29]], 'date-time': '2024-03-29T11:51:30Z', 'timestamp': 1711713090656}, 'reference-count': 33, 'publisher': 'Public Library of Science (PLoS)', 'issue': '2', 'license': [ { 'start': { 'date-parts': [[2021, 2, 16]], 'date-time': '2021-02-16T00:00:00Z', 'timestamp': 1613433600000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://creativecommons.org/licenses/by/4.0/'}], 'content-domain': {'domain': ['www.plosone.org'], 'crossmark-restriction': False}, 'abstract': '<jats:sec id="sec001">\n' '<jats:title>Background</jats:title>\n' '<jats:p>Ivermectin is one among several potential drugs explored for its therapeutic and ' 'preventive role in SARS-CoV-2 infection. The study was aimed to explore the association ' 'between ivermectin prophylaxis and the development of SARS-CoV-2 infection among healthcare ' 'workers.</jats:p>\n' '</jats:sec>\n' '<jats:sec id="sec002">\n' '<jats:title>Methods</jats:title>\n' '<jats:p>A hospital-based matched case-control study was conducted among healthcare workers of ' 'AIIMS Bhubaneswar, India, from September to October 2020. Profession, gender, age and date of ' 'diagnosis were matched for 186 case-control pairs. Cases and controls were healthcare workers ' 'who tested positive and negative, respectively, for COVID-19 by RT-PCR. Exposure was defined ' 'as the intake of ivermectin and/or hydroxychloroquine and/or vitamin-C and/or other ' 'prophylaxis for COVID-19. Data collection and entry was done in Epicollect5, and analysis was ' 'performed using STATA version 13. Conditional logistic regression models were used to ' 'describe the associated factors for SARS-CoV-2 infection.</jats:p>\n' '</jats:sec>\n' '<jats:sec id="sec003">\n' '<jats:title>Results</jats:title>\n' '<jats:p>Ivermectin prophylaxis was taken by 76 controls and 41 cases. Two-dose ivermectin ' 'prophylaxis (AOR 0.27, 95% CI, 0.15–0.51) was associated with a 73% reduction of SARS-CoV-2 ' 'infection among healthcare workers for the following month. Those involved in physical ' 'activity (AOR 3.06 95% CI, 1.18–7.93) for more than an hour/day were more likely to contract ' 'SARS-CoV-2 infection. Type of household, COVID duty, single-dose ivermectin prophylaxis, ' 'vitamin-C prophylaxis and hydroxychloroquine prophylaxis were not associated with SARS-CoV-2 ' 'infection.</jats:p>\n' '</jats:sec>\n' '<jats:sec id="sec004">\n' '<jats:title>Conclusion</jats:title>\n' '<jats:p>Two-dose ivermectin prophylaxis at a dose of 300 μg/kg with a gap of 72 hours was ' 'associated with a 73% reduction of SARS-CoV-2 infection among healthcare workers for the ' 'following month. Chemoprophylaxis has relevance in the containment of pandemic.</jats:p>\n' '</jats:sec>', 'DOI': '10.1371/journal.pone.0247163', 'type': 'journal-article', 'created': {'date-parts': [[2021, 2, 16]], 'date-time': '2021-02-16T22:17:46Z', 'timestamp': 1613513866000}, 'page': 'e0247163', 'update-policy': 'http://dx.doi.org/10.1371/journal.pone.corrections_policy', 'source': 'Crossref', 'is-referenced-by-count': 44, 'title': 'Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: ' 'A matched case-control study', 'prefix': '10.1371', 'volume': '16', 'author': [ {'given': 'Priyamadhaba', 'family': 'Behera', 'sequence': 'first', 'affiliation': []}, {'given': 'Binod Kumar', 'family': 'Patro', 'sequence': 'additional', 'affiliation': []}, {'given': 'Arvind Kumar', 'family': 'Singh', 'sequence': 'additional', 'affiliation': []}, { 'given': 'Pradnya Dilip', 'family': 'Chandanshive', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0003-0297-0177', 'authenticated-orcid': True, 'given': 'Ravikumar', 'family': 'S. R.', 'sequence': 'additional', 'affiliation': []}, {'given': 'Somen Kumar', 'family': 'Pradhan', 'sequence': 'additional', 'affiliation': []}, { 'given': 'Siva Santosh Kumar', 'family': 'Pentapati', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0001-7134-8395', 'authenticated-orcid': True, 'given': 'Gitanjali', 'family': 'Batmanabane', 'sequence': 'additional', 'affiliation': []}, { 'given': 'Prasanta Raghab', 'family': 'Mohapatra', 'sequence': 'additional', 'affiliation': []}, {'given': 'Biswa Mohan', 'family': 'Padhy', 'sequence': 'additional', 'affiliation': []}, {'given': 'Shakti Kumar', 'family': 'Bal', 'sequence': 'additional', 'affiliation': []}, {'given': 'Sudipta Ranjan', 'family': 'Singh', 'sequence': 'additional', 'affiliation': []}, {'given': 'Rashmi Ranjan', 'family': 'Mohanty', 'sequence': 'additional', 'affiliation': []}], 'member': '340', 'published-online': {'date-parts': [[2021, 2, 16]]}, 'reference': [ { 'key': 'pone.0247163.ref001', 'unstructured': 'WHO Coronavirus Disease (COVID-19) Dashboard [Internet]. The World ' 'Health Organization; c2021- [cited 2020 Nov 6]. Available from: ' 'https://covid19.who.int.'}, { 'key': 'pone.0247163.ref002', 'unstructured': 'Ministry of Health and Family Welfare [Internet]. Government of India; ' 'c2021- [cited 2020 Nov 6]. Available from: https://www.mohfw.gov.in/.'}, { 'issue': '14', 'key': 'pone.0247163.ref003', 'first-page': '7861', 'article-title': 'Clinical features, laboratory findings and predictors of death in ' 'hospitalized patients with COVID-19 in Sardinia, Italy', 'volume': '24', 'author': 'D Vito', 'year': '2020', 'journal-title': 'Eur Rev Med Pharmacol Sci'}, { 'issue': '7', 'key': 'pone.0247163.ref004', 'doi-asserted-by': 'crossref', 'DOI': '10.1002/hed.26269', 'article-title': 'Olfactory and gustatory function impairment in COVID-19 patients: ' 'Italian objective multicenter-study', 'volume': '42', 'author': 'LA Vaira', 'year': '2020', 'journal-title': 'Head & Neck'}, { 'issue': '6', 'key': 'pone.0247163.ref005', 'doi-asserted-by': 'crossref', 'DOI': '10.1002/hed.26204', 'article-title': 'Objective evaluation of anosmia and ageusia in COVID-19 patients: ' 'Single-center experience on 72 cases', 'volume': '42', 'author': 'LA Vaira', 'year': '2020', 'journal-title': 'Head and Neck'}, { 'issue': '6', 'key': 'pone.0247163.ref006', 'doi-asserted-by': 'crossref', 'first-page': 'e30', 'DOI': '10.1097/IPC.0000000000000952', 'article-title': 'A Case of Vasculities-Like Skin Eruption Associated With COVID-19', 'volume': '28', 'author': 'N Geremia', 'year': '2020', 'journal-title': 'Infectious Diseases in Clinical Practice'}, { 'issue': '1', 'key': 'pone.0247163.ref007', 'first-page': '24', 'article-title': 'Silent COVID-19: what your skin can reveal', 'volume': '21', 'author': 'C Guarneri', 'year': '2021', 'journal-title': 'Infectious Diseases'}, { 'key': 'pone.0247163.ref008', 'article-title': 'Infection and death in healthcare workers due to COVID-19: a systematic ' 'review', 'volume': '33', 'author': 'G Sant’Ana', 'year': '2020', 'journal-title': 'Acta Paul Enferm'}, { 'key': 'pone.0247163.ref009', 'unstructured': 'COVID-19 has infected some 570,000 health workers and killed 2,500 in ' 'the Americas, PAHO Director says—PAHO/WHO. [Internet]. Pan American ' 'Health Organization; c2020- [cited 2020 Nov 6]. Available from: ' 'http://www.paho.org/en/news/2-9-2020-covid-19-has-infected-some-570000-health-workers-and-killed-2500-americas-paho.'}, { 'issue': 'SI-1', 'key': 'pone.0247163.ref010', 'doi-asserted-by': 'crossref', 'first-page': '578', 'DOI': '10.3906/sag-2004-132', 'article-title': 'Protective measures for COVID-19 for healthcare providers and ' 'laboratory personnel', 'volume': '50', 'author': 'C Ağalar', 'year': '2020', 'journal-title': 'Turk J Med Sci'}, { 'key': '#cr-split#-pone.0247163.ref011.1', 'unstructured': 'Coronavirus Disease 2019 (COVID-19) [Internet]. Centers for Disease ' 'Control and Prevention'}, { 'key': '#cr-split#-pone.0247163.ref011.2', 'unstructured': 'c2020- [cited 2020 Nov 6]. Available from: ' 'https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control.html.'}, { 'key': 'pone.0247163.ref012', 'unstructured': 'Coronavirus disease (covid-19) outbreak: rights, roles and ' 'responsibilities of health workers, including key considerations for ' 'occupational safety and health: Interim guidance. [Internet]. World ' 'Health Organization; c2020- [cited 2020 Nov 6]. Available from: ' 'https://www.who.int/docs/default-source/coronaviruse/who-rights-roles-respon-hw-covid-19.pdf?sfvrsn=bcabd401_0.'}, { 'issue': '9', 'key': 'pone.0247163.ref013', 'doi-asserted-by': 'crossref', 'first-page': '606', 'DOI': '10.1016/j.arbres.2020.05.008', 'article-title': 'Hydroxychloroquine as prophylaxis for coronavirus SARS-CoV-2 infection: ' 'review of the ongoing clinical trials', 'volume': '56', 'author': 'V Galvis', 'year': '2020', 'journal-title': 'Arch Bronconeumol'}, { 'key': 'pone.0247163.ref014', 'unstructured': 'Revised advisory on the use of Hydroxychloroquine (HCQ) as prophylaxis ' 'for SARS-CoV-2 infection (in suppression of previous advisory date 23rd ' 'March, 2020) [Internet]. Ministry of Health and Family Welfare; c2020- ' '[cited 2020 Nov 6]. Available from: ' 'https://www.mohfw.gov.in/pdf/RevisedadvisoryontheuseofhydroxychloroquineasprophylaxisforSARSCOVID19infection.pdf.'}, { 'key': 'pone.0247163.ref015', 'unstructured': 'Coronavirus disease (COVID-19): Hydroxychloroquine [Internet]. World ' 'Health Organisation; c2020- [cited 2020 Nov 6]. Available from: ' 'https://www.who.int/news-room/q-a-detail/coronavirus-disease-covid-19-hydroxychloroquine.'}, { 'key': 'pone.0247163.ref016', 'unstructured': 'Mahmud DR. A Phase III Trial to Promote Recovery From Covid 19 With ' 'Combined Doxycycline and Ivermectin Along Standard Care. ' 'clinicaltrials.gov Report No.: results/NCT04523831. [Internet]. 2020 Oct ' '[cited 2020 Nov 4]. Available from: ' 'https://clinicaltrials.gov/ct2/show/results/NCT04523831.'}, { 'key': 'pone.0247163.ref017', 'unstructured': 'Shouman W. Use of Ivermectin as a Prophylactic Option in Asymptomatic ' 'Family Close Contact for Patient With COVID-19. clinicaltrials.gov ' 'Report No.: NCT04422561 [Internet]. 2020 Aug [cited 2020 Nov 4]. ' 'Available from: https://clinicaltrials.gov/ct2/show/NCT04422561.'}, { 'key': 'pone.0247163.ref018', 'article-title': 'COVID-19: ivermectin prophylaxis in adult contacts. First Report on ' 'Health Personnel and Post-Exposure Prophylaxis', 'author': 'G Aguirre Chang', 'year': '2020', 'journal-title': 'Research Gate'}, { 'issue': '1', 'key': 'pone.0247163.ref019', 'first-page': '85', 'article-title': 'Use of Ivermectin is Associated with Lower Mortality in Hospitalized ' 'Patients with COVID-19 (ICON study)', 'volume': '159', 'author': 'JC Rajter', 'year': '2020', 'journal-title': 'Chest'}, { 'key': 'pone.0247163.ref020', 'unstructured': 'nMaster. Version2.0—Sample Size Software. [Software]. Department of ' 'Biostatistics, CMC, Vellore [cited 2020 Nov 6]. Available from: ' 'http://www.cmc-biostatistics.ac.in/nmaster/.'}, { 'key': 'pone.0247163.ref021', 'unstructured': 'Health workers exposure risk assessment and management in the context of ' 'COVID-19 virus: interim guidance [Internet]. World Health Organization; ' 'c2020 Mar 4- [cited 2020 Nov 6]. Available from: ' 'https://apps.who.int/iris/handle/10665/331340.'}, { 'key': 'pone.0247163.ref022', 'unstructured': 'Ministry of Health and Family Welfare, Government of India. Advisory on ' 'the use of Hydroxychloroquine as prophylaxis for SARS-CoV-2 Infection. ' '[Internet] 2020 [cited 2021 Jan 20]. Available from: ' 'https://www.mohfw.gov.in/pdf/ ' 'AdvisoryontheuseofHydroxychloroquinasprophylaxisforSARSCoV2infection.pdf.'}, { 'key': 'pone.0247163.ref023', 'first-page': '1', 'article-title': 'COVID-19 and social distancing', 'author': 'M Qian', 'year': '2020', 'journal-title': 'Z Gesundh Wiss'}, { 'key': 'pone.0247163.ref024', 'doi-asserted-by': 'crossref', 'first-page': '18', 'DOI': '10.1016/j.ijid.2020.06.062', 'article-title': 'COVID-19 preventive measures showing an unintended decline in ' 'infectious diseases in Taiwan', 'volume': '98', 'author': 'CJ Galvin', 'year': '2020', 'journal-title': 'Int J Infect Dis'}, { 'issue': '12', 'key': 'pone.0247163.ref025', 'doi-asserted-by': 'crossref', 'first-page': 'e1003499', 'DOI': '10.1371/journal.pmed.1003499', 'article-title': 'Impact of self-imposed prevention measures and short-term government ' 'intervention on mitigating and delaying a COVID-19 epidemic: A ' 'modelling study', 'volume': '17', 'author': 'A Teslya', 'year': '2020', 'journal-title': 'PLOS Medicine'}, { 'issue': '6', 'key': 'pone.0247163.ref026', 'doi-asserted-by': 'crossref', 'first-page': '156', 'DOI': '10.4103/ijph.IJPH_464_20', 'article-title': 'Effectiveness of preventive measures against COVID-19: A systematic ' 'review of In Silico modeling studies in indian context', 'volume': '64', 'author': 'A Lahiri', 'year': '2020', 'journal-title': 'Indian J Public Health'}, { 'issue': '10', 'key': 'pone.0247163.ref027', 'doi-asserted-by': 'crossref', 'first-page': '2361', 'DOI': '10.3201/eid2610.201702', 'article-title': 'Impact of social distancing measures on coronavirus disease healthcare ' 'demand, central Texas, USA', 'volume': '26', 'author': 'X Wang', 'year': '2020', 'journal-title': 'Emerg Infect Dis'}, { 'key': 'pone.0247163.ref028', 'doi-asserted-by': 'crossref', 'first-page': '104787', 'DOI': '10.1016/j.antiviral.2020.104787', 'article-title': 'The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 ' 'in vitro', 'author': 'L Caly', 'year': '2020', 'journal-title': 'Antiviral Res'}, { 'issue': '6', 'key': 'pone.0247163.ref029', 'doi-asserted-by': 'crossref', 'first-page': '517', 'DOI': '10.1056/NEJMoa2016638', 'article-title': 'A randomized trial of hydroxychloroquine as postexposure prophylaxis ' 'for Covid-19', 'volume': '383', 'author': 'DR Boulware', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'key': 'pone.0247163.ref030', 'doi-asserted-by': 'crossref', 'first-page': '1451', 'DOI': '10.3389/fimmu.2020.01451', 'article-title': 'Quercetin and vitamin C: an experimental, synergistic therapy for the ' 'prevention and treatment of SARS-CoV-2 related disease (COVID-19)', 'volume': '11', 'author': 'RML Colunga Biancatelli', 'year': '2020', 'journal-title': 'Front Immunol'}, { 'key': 'pone.0247163.ref031', 'doi-asserted-by': 'crossref', 'first-page': '2164956120934768', 'DOI': '10.1177/2164956120934768', 'article-title': 'Ascorbate as Prophylaxis and Therapy for COVID-19—Update From Shanghai ' 'and US Medical Institutions', 'volume': '9', 'author': 'RZ Cheng', 'year': '2020', 'journal-title': 'Glob Adv Health Med'}, { 'key': 'pone.0247163.ref032', 'doi-asserted-by': 'crossref', 'first-page': '110948', 'DOI': '10.1016/j.nut.2020.110948', 'article-title': 'Vitamin C as prophylaxis and adjunctive medical treatment for COVID-19?', 'volume': '79', 'author': 'AF Feyaerts', 'year': '2020', 'journal-title': 'Nutrition'}], 'container-title': 'PLOS ONE', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://dx.plos.org/10.1371/journal.pone.0247163', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2021, 2, 16]], 'date-time': '2021-02-16T22:18:23Z', 'timestamp': 1613513903000}, 'score': 1, 'resource': {'primary': {'URL': 'https://dx.plos.org/10.1371/journal.pone.0247163'}}, 'subtitle': [], 'editor': [{'given': 'Muhammad', 'family': 'Adrish', 'sequence': 'first', 'affiliation': []}], 'short-title': [], 'issued': {'date-parts': [[2021, 2, 16]]}, 'references-count': 33, 'journal-issue': {'issue': '2', 'published-online': {'date-parts': [[2021, 2, 16]]}}, 'URL': 'http://dx.doi.org/10.1371/journal.pone.0247163', 'relation': {}, 'ISSN': ['1932-6203'], 'subject': ['Multidisciplinary'], 'container-title-short': 'PLoS ONE', 'published': {'date-parts': [[2021, 2, 16]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit